Medi-Cal Rx to require prior authorization for migraine med Reyvow

January 16, 2024

Effective February 1, 2024, Medi-Cal Rx will require prior authorization (PA) for Reyvow (lasmiditan succinate), which is used to treat migraines. PAs will be required for new and renewing prescriptions.

Alternatives not requiring a PA request are listed on the Medi-Cal Rx Contract Drugs List and include:

  • Imitrex (sumatriptan)
  • Amerge (naratriptan)
  • Maxalt and Maxalt-MLT (rizatriptan)
  • Nurtec ODT (rimegepant)
  • Ubrelvy (ubrogepant)
  • Ergotamine/caffeine

For more information, see the announcement.

Questions? Contact the Medi-Cal Rx Customer Service Center (CSC) at (800) 977-2273 or MediCalRxEducationOutreach@magellanhealth.com.


Was this article helpful?    
Download the New CMADocs app!

Download the new CMADocs app!

CMA's new mobile app lets you connect with your colleagues and engage with CMA content!  Download the "CMADocs" app today from the Apple or Google Play app stores for daily news updates, events calendar, resource library and more.

Latest News

Load More